APECED: JAK Inhibition in an Adult Case with Long-Term Follow-Up

This case study discusses a 37-year-old female with APECED, a rare autoimmune disease, who showed significant clinical improvement after 11 months of treatment with the JAK inhibitor ruxolitinib. The patient experienced hair regrowth, resolution of plantar verruca, and partial improvement of onychodystrophy. This case is notable for the patient's adult age, as APECED typically affects adolescents or young adults. The study suggests that JAK inhibitors may be effective in managing APECED by targeting the JAK/STAT pathways, potentially improving the quality of life for patients with this complex, multisystemic condition.